This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Neutel, J. M Search for Related Content PubMed PubMed Citation Articles by Neutel, J. M Social Bookmarking                         What's this?

Hypertension and its management: a problem in need of new treatment strategies

Veterans Affairs Medical Center, Long Beach, California, University of California, Irvine, USA, JMNeutel@ aol.com

Although treatments of hypertension have significantly decreased morbidity and mortality from cerebrovascular disease, the associated reductions in coronary artery disease have been very disappointing. Hypertension is a complex inherited syndrome of cardiovascular risk factors, all of which contribute to the development of heart disease. Angiotensin II receptor blockers (ARBs), such as the highly selective ARB valsartan, provide an alternative treatment strategy to address the multiple issues in coronary artery disease. These agents are well-tolerated and have a once-daily regimen that improves compliance. They bring multiple cardiovascular benefits beyond blood pressure (BP) control, such as renoprotection and cardiovascular growth reduction.

Key Words: antihypertensive treatments • compliance • adverse events • systolic blood pressure • combination therapy

References

• Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-98.[Abstract/Free Full Text]
• Burt VL, Culter JA, Higgins M. et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26:60-9.[Abstract/Free Full Text]
• Marques-Vidal P., Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens 1997; 11: 213-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nieto JF, Alfonso J., Chambless LE et al. Population awareness and control of hypertension and hypercholesterolemia: The Atherosclerosis Risk in Communities Study. Intern Med 1995; 155:677-84.[CrossRef]
• The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA 1976; 235: 825-7.[Abstract/Free Full Text]
• UK Propective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 7160: 703-13.
• Bodin F. Pharmacological and clinical profile of valsartan. J Hypertens 2000; 18: S1-S7.
• Neutel JM, Bedigian MP Efficacy of valsartan in patients aged 65 years with systolic hypertension Clin Ther 2000; 22: 961-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Neutel J.,Weber M., Pool J. et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19: 447-58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Merck & Co., Inc. Pennsylvania. Database on file.
• Langtry HD, McClellan KJ Valsartan/hydrochlorothiazide Drugs 1999; 57: 751-5.
• Neaton JD, Wentworth DN, Cutler J. et al. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group. Ann Epidemiol 1993; 3: 493-9.[Medline] [Order article via Infotrieve]
• Havlik H., La Croix A., Kleinman J., Ingram D., Harris T., Cornoni-Huntley J. Antihypertensive drug therapy and survival by treatment status in a national study. Hypertension 1989; 13 (suppl 1): 1-28-1-32.
• de las Heras N.,Aragoncillo P., Maeso R. et al. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999; 34: 969-75.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 2 suppl, S10-S13 (2000)
DOI: 10.3317/jraas.2000.046


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Neutel, J. M Search for Related Content PubMed PubMed Citation Articles by Neutel, J. M Social Bookmarking                         What's this?